Our study identified SGLT-2 inhibitors as protective from COVID-19 hospitalization (OR 0.430; 95% CI 0.257–0.719), and SARS-CoV-2 infection (OR 0.607; 95% CI 0.448–0.823). Here, SLC5A2 is linked to COVID-19.